Latest News !
 

WEHI $405m+ Canada Venetoclax For Cancer Deal

10-Year BDI-40 Up 80%, ASX200 Down 9% Big Caps Up 270%

Dr Boreham's Crucible: Airxpanders

Innate Tumbles 93% On MIS416 Fail For Multiple Sclerosis

Monash Research Leads To ASC Warning On Assay Hit Pains 

Budget 2017: 1st MRFF Funds, Steady As She Goes
- Biotech Daily Editorial Comment

Biotech Daily Editorial: Welcome To 2017 

2016 - The Year In Review: Money, Malcolm & Medical Marijuana

Novartis Buys Spinifex For $916m

 

 

July BDI-40 Down 4%, Big Caps 8%, ASX200 Flat

Acrux Up 39%, Atcor, LBT 25%; Compumedics Down 29%; Psivida 28%

Aug 1, 2017

July was patchy for the Biotech Daily Top 40 Index, which fell 4.3 percent, with most of the Top 20 companies down and most of the Second 20 companies up. Sixteen of the BDI-40 companies were up, 22 fell with two unchanged.

 

The ASX200 slipped one point or 0.02 percent to 5,721 points in July, while the Nasdaq Biotechnology Index (NBI) improved 2.9 percent.

 

The three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) fell a collective 8.0 percent in July, with CSL retreating 8.9 percent to $57,073 million, Cochlear down 8.1 percent to $8,203 million and Resmed easing 3.8 percent to $13,696 million. For the year to July 31, the Big Caps improved a collective 6.2 percent.

 

In the 12 months to July 31, the BDI-40 fell 14.2 percent, nearly all of the fall due to the Sirtex loss of $886 million or 48.8 percent of its market capitalization, with Impedimed down $238 million (47.7%) and Nanosonics retreating $108 million (13.3%).

 

In the same period, the ASX200 was up 2.9 percent and the NBI climbed 10.3 percent.

 

Last month’s 64.7 percent best, Compumedics, led the July falls by percentage, down $32 million or 28.6 percent to $80 million, while the biggest dollar fall in market capitalization was Mesoblast down $132 million (14.8%), with Nanosonics down $53 million (7.0%). Psivida fell $26 million or 27.95 percent to $67 million, its lowest market capitalization since April 2013, followed by Viralytics (16.3%), Mesoblast (14.8%) and Orthocell (14.8%).

 

Acrux was the best, recovering 38.9 percent to $50 million, but a long way from its peak of $723 million in May 2012. Both Atcor and LBT improved 25 percent to $10 million and $45 million, respectively, followed by Dimerix (22.2%), Bionomics (15%), Genetic Signatures (15%), Living Cell (12.7%) and Prana (11.1%).

 

Outside the BDI-40, Volpara reached its highest market capitalization since listing of $55 million, Medlab Clinical was up 67.9 percent to $141 million, IQ3 was up 24 percent to $31 million, while Adherium adhered to its all-time low of $18 million. In the US, Aviragen (Biota) fell 20.6 percent to $27 million, Queensland’s Protagonist was up 3.6 percent to $257 million and Israel’s Redhill climbed 9.95 percent to $210 million.

 

BDI-40 v S&P ASX200 Jun 30, 2006 to Jul 31, 2017 

 

BDI-40 v S&P ASX200 Jul 31, 2016 to Jul 31, 2017 

 

Big Caps (Cochlear, CSL, Resmed) Year To Jul 31, 2017